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Abstract
Background—While the detrimental effects of smoking among HIV positive patients have been
well documented, there is a paucity of data regarding cigarette smoking prevalence among these
patients in South Africa.
Objectives—To establish the frequency, demographics, and knowledge of harmful effects and of
smoking cessation strategies among HIV-positive patients in Johannesburg, South Africa.
Methods—A prospective cross-sectional survey, using a structured questionnaire interview, of
HIV-positive patients attending the HIV Clinic at the Charlotte Maxeke Johannesburg Academic
Hospital between 1 July 2011 and 31 October 2011.
Results—Of 207 HIV positive patients attending an ARV roll-out clinic, 31 (15%) were current
smokers (23% of the males and 7.5% of the females) and a further 45 (21.7%) were ex-smokers.
Most of the current smokers (30/31 patients) indicated their wish to quit smoking, and among the
group as a whole most patients were aware of the general (82.5%) and HIV-related (77.8%) risks
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of smoking and of methods of quitting smoking. Despite this, however, most (61.8%) were not
aware of whom they could approach for assistance and advice.
Conclusions—Given the relatively high prevalence of current and ex-smokers amongst HIV
positive patients there is a need for the introduction of smoking cessation strategies and assistance
at HIV-rollout clinics in South Africa.
Introduction
The success of anti-smoking policies implemented in many developed countries has to a
large extent been countered by the efforts of a highly resilient tobacco industry to target
developing countries, many of which have less stringent anti-smoking strategies. Indeed
developing countries are now estimated to account for >70% of global tobacco
consumption.[1,2] The increase in the frequency of smoking has coincided with the HIV/
AIDS pandemic in developing countries, presenting an ominous, interactive threat to public
health. This is based on a number of studies, mainly from the USA and Europe, reporting
that HIV-infected persons have extremely high rates of cigarette smoking,[3,4] associated, in
turn, with a higher than expected increase in the frequency of co-morbidities, including
cardiovascular diseases, bacterial pneumonia, and cancers, as well as increased
mortality.[3–6] Despite unrestricted access to advanced care and therapy, HIV-positive
smokers appear to lose more life years from smoking than from HIV infection. [5] Moreover,
smoking not only impacts negatively on the efficacy of anti-retroviral therapy,[7] but is also
associated with treatment failure in tuberculosis.[8]
Although the frequency of cigarette smoking in the general population in South Africa,
home to the largest number of HIV-positive people in the world, is estimated to be 16%,[9]
the frequency in HIV positive persons is uncertain. In a small pre-antiretroviral therapy
(ART) study conducted in a group (n=41) of predominantly male (n=34) subjects with
pulmonary tuberculosis, the frequencies of cigarette smoking, measured according to urine
cotinine concentrations, in the entire group, as well as in a sub-group of HIV-seropositive
patients (n=10) were reported to be 63% and 70% respectively, with the cotinine
concentrations rising significantly after 6 months of therapy.[10] These figures are
comparable with a more recent study in a larger number of South African patients with
active or latent TB in which the reported frequencies of cigarette smoking for the entire
group (n=424) and the HIV-positive sub-group (n=119) were 68% and 71% respectively.[11]
Given the relative paucity of data on this priority public health issue,[12] the current study
was undertaken to establish the frequency and demographics of cigarette smoking and other
types of substance abuse among HIV-positive patients attending the HIV Clinic at Charlotte
Maxeke Johannesburg Academic Hospital, in Johannesburg, South Africa.
Patients and Methods
This was a prospective cross-sectional survey of HIV-positive patients attending the HIV
Clinic at the Charlotte Maxeke Johannesburg Academic Hospital in Johannesburg, South
Africa, between 1 July 2011 and 31 October 2011. The hospital is a tertiary academic
institution, which has an HIV clinic providing antiretrovirals. All patients entered into the
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study gave signed informed consent for participation in the study, which was approved by
the Human Research Ethics Committee of the University of the Witwatersrand.
All patients who agreed to participate were interviewed using a structured questionnaire
with recording of demographic and clinical details and a detailed history of smoking status.
Patients were also questioned about their knowledge of overall harmful effects of smoking,
as well as the effects of smoking on the HIV infection, their knowledge of smoking
cessation strategies and previous attempts to quit. In 147 patients, who provided a urine
sample, this specimen was subsequently tested for cotinine levels using a solid phase
competitive ELISA procedure (Calbiotech Inc., Spring Valley, CA, USA) the results of
which are expressed as nanograms (ng)/millilitre (ml). For the purpose of this study, a value
of >25ng/ml was considered to be indicative of active smoking, as it has been suggested that
values up to 30ng/ml may be associated with passive smoking.
Data collected was entered into data sheets. Basic frequency analyses were used to describe
the mean values and ranges on continuous variables, whereas proportions were used in the
case of non-continuous variables.
Results
A total of 207 patients was entered into the database, of which 108 (52.2%) were female.
The overwhelming majority of patients were black (94.2%), reflecting the overall
demographics of the clinic (white patients 2.9% and coloured patients 2.9%). The mean age
of the patients was 39.9 years with a range of 19–62 years.
Overall, 31/207 (15%) were self-described current smokers, of which 23/100 were male
(23% of males) and 8/107 were female (7.5% of females). An additional 45/207 cases
(21.7%) indicated that they were ex-smokers and 130/207 (62.8%) indicated that they had
never smoked. Two patients indicated that they were current smokers of cannabis in addition
to cigarettes. In addition 6 patients indicated that they also currently used snuff. The average
age of onset of smoking was 20 years of age (range 9–46 years). The average number of
cigarettes smoked per day was 9 (range 1–30 cigarettes per day).
Overall 30/31(96.7%) of the smokers indicated that they wished to stop smoking. The
reasons indicated by the current and ex-smokers for wishing to quit smoking are shown in
Table 1. The majority of patients wished to quit because of concerns regarding health issues,
but there were other motivations, including HIV infection diagnosis, concurrent illness,
costs and also personal, family, and religious concerns. A majority of the total patient
population (170/206 (82.5%)) indicated that they knew about the potential harmful effects of
cigarette smoking in general (Table 2), although several participants could not name a
specific health hazard when questioned further (Table 2). A majority (161/207 (77.8%)) also
indicated their knowledge of the potential harmful effects of cigarette smoking, specifically
in relation to HIV infection. Of the latter group of patients, 34/207 (16.4%) believed there
were no harmful effects of smoking on HIV infection and 12/207 (5.8%) were unsure.
Overall, 64/76 (84.2%) current and ex-smokers had attempted quitting, while 12/76 (15.8%)
had not. A majority of the total patient population (58%) indicated an awareness of methods
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of quitting smoking, while 40.1% did not know (data not available in 1.9%). Most patients
(62.3%) were unaware of the resources available for advice and assistance.
As indicated in Table 3, 82 patients were unaware of smoking cessation agents/adjuncts, 66
patients indicated that various food substances and drinks were of value, 35 patients
indicated their knowledge of going “cold turkey”, 33 patients were unable to name
techniques even though they had indicated their knowledge of such, 33 patients indicated
various other forms of assistance including psychotherapy, avoiding smokers and drinkers,
keeping busy, exercise, religion and prayer, rehabilitation and hypnotherapy, 20 described
various forms of nicotine replacement therapy (patches, gum, and sprays), 11 patients
described various drugs, such as buproprion, 9 patients described weaning from smoking
and 9 patients described various forms of cigarettes (electronic, nicotine-containing or
nicotine-free cigarettes), and no data were recorded in 5 patients.
Urine specimens were available for the measurement of cotinine levels in 141 of the
patients. Of these 21 patients had indicated that they were current smokers, 31 that they were
ex-smokers and 91 that they were non-smokers (Table 4). Cotinine levels were raised (>
25ng/ml) in 43/141 patients (30.5%), of whom 21 had indicated that they were non-smokers,
10 that they were ex-smokers and 12 that they were current smokers. An additional 9 of
those patients that had indicated that they were smokers did not have raised cotinine levels.
All female patients indicating that they were smokers had raised cotinine levels, while 6 of
the male patients who indicated they were smokers had raised levels, and an additional 9
male smokers had cotinine levels that were not in the positive range
Discussion
The main findings of this study of 207 HIV-infected patients attending an ARV roll-out
clinic were that 15% were current smokers and that most of the patients who were current or
ex-smokers had indicated their wish to quit smoking. Furthermore, among all the patients,
most were aware of the general (82.5%) and HIV-related (77.8%) risks of smoking, and of
methods of quitting smoking, but most (61.8%) also indicated that they were not aware of
resources available for assistance and advice.
The overall prevalence of current smoking in the present study, based on the patient history,
was 15%. This is similar to the frequency of smoking previously estimated in the general
population in South Africa,[9] but much lower than that found in previous studies of HIV-
infected persons in South Africa.[9–11] Factors that may have contributed include the fact
that this is a predominantly black South African population known to smoke less than any of
the other population groups in the country, and furthermore that there was a greater
proportion of females in the present study, with a previous study[9] having indicated that
black females are much less likely to smoke.
However, the true frequency of smoking in this study group may have been underestimated,
since it was based on the patient history alone, whereas the urine cotinine levels were
actually raised in 43/141 patients (30.5%). The discrepancy rate between the smoking
history recorded and the measured urine cotinine levels was 28.4% (40/141 patients) in the
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study cohort, as indicated in Table 4. In 19 of the males who indicated that they were either
ex-smokers or non-smokers, the cotinine levels were actually raised (Table 4). Thus the
frequency of smoking would have been recorded as being higher if this was based on the
urine cotinine levels alone or the urine cotinine levels together with the history. The exact
reasons for these discrepancies are uncertain, and while a discrepant history alone may be
the major reason, it would be interesting to speculate that this may possibly relate to the
relatively low numbers of cigarettes smoked or even to intermittent smoking. Exposure to
biomass fuel is not a consideration since nicotine is contained only in tobacco leaves (and in
the leaves of some other plants). Furthermore, passive exposure to cigarette smoke could
have played a role, but we did not record details of possible passive smoking among the
patients, either in the community or in their homes.
Interestingly, there were additional discrepancies between the patient history and the urine
cotinine levels in that in 9 males who indicated they were current smokers the urine cotinine
levels were not found to be raised (Table 4). Once again the exact reasons for this are
uncertain, but there is no indication in the current study as to what time of day the urine
cotinine specimens were taken, particularly in relation to the last cigarette smoked. Cotinine
is the major metabolite of nicotine. It has a comparatively long half-life of about 17 hours in
body fluid and is widely accepted as a sensitive and reliable marker of exposure to cigarette
smoke and is considered to be more reliable than smoking history in determining smoking
status[12]. Thus while these discrepant results are in contrast to previous studies which have
suggested there was a good correlation between smoking history and serum cotinine
levels[11] there are other studies indicating that there is a relatively poor correlation between
patient history and the urine cotinine levels, especially in ex-smokers in whom smoking
history can be very misleading.[13]
Encouragingly, most of the study population had insight into the general health and HIV-
associated risks of smoking and almost all the ever-smokers indicated their willingness to
quit smoking, but most of the study population indicated their lack of knowledge of
resources that they could access for assistance and advice, suggesting an immediate public
health intervention possibility
The impact of cigarette smoking in HIV-infected persons is considerable, and remains so
even subsequent to the introduction of highly active antiretroviral therapy.[4] Cigarette
smoking impacts on mortality, quality of life and comorbid illnesses in HIV-infected
patients.[3] It is extremely well documented in HIV-infected individuals that there are a
myriad of serious medical conditions associated with cigarette smoking, including
cardiovascular disease, pulmonary diseases and cancers,[14] with further good evidence in a
number of these conditions that these risks decrease on smoking cessation. Although the
prevalence of smoking in the current study is substantially lower than that reported in
developed countries, the overwhelming infectious disease burden in the developing world
compounds its adverse effects. For this reason it is incumbent on all healthcare workers
looking after HIV-infected persons to actively encourage and support efforts among their
patients to stop smoking.[4,15]
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Table 1
Reasons given by current and ex-smokers for wishing to quit (n=76).
Health concerns 37
Finances 8
HIV diagnosis 7
Personal reasons 7
Concurrent illness 6
Other 5
Did not indicate a reason 2
Family reasons 2
Religion 2
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Table 2
The health-related effects identified by those patients indicating a knowledge of harmful effects of cigarette
smoking (n=170)*
Cancer 52
Tuberculosis 41
Emphysema 37
Not able to name a harmful effect 32+
Bad body odour 24
Effects on HIV medication 3
*
sometimes multiple
+
not able to name a harmful effect even those they had indicated they were aware of harmful effects
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Table 3
Knowledge of methods used as part of smoking cessation strategies (n = 207)*
Patient not know of any techniques 82
Use of food-related items 66+
Going “cold turkey” 35
Unable to name a technique 33++
Varied other methods 33
Forms of nicotine replacement therapy 20
Tablets/buproprion 11
Specialised cigarettes 9
Weaning 9
Data unknown 5
*Sometimes multiple. Please refer to text for more complete details
+
Most commonly the use of sweets and chewing gum were indicated
++Unable to name a technique even though they had indicated knowledge of different techniques
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